Company Profile

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01020Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE2307.00-39.25 (-1.67 % )
PREV CLOSE (Rs.) 2346.25
OPEN PRICE (Rs.) 2335.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 88849
TODAY'S LOW / HIGH (Rs.)2281.00 2397.40
52 WK LOW / HIGH (Rs.)1786.05 2767.1
NSE2309.20 -32.95 (-1.41 % )
PREV CLOSE(Rs.) 2342.15
OPEN PRICE (Rs.) 2335.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 2309.20 (270 )
VOLUME 456915
TODAY'S LOW / HIGH(Rs.) 2281.60 2400.00
52 WK LOW / HIGH (Rs.)1785.4 2766.2

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.35
TTM EPS (Rs.) 76.61
P/E Ratio 30.11
Book Value (Rs.) 397.11
Face Value (Rs.) 2
MCap (Rs. in Mn) 292647.82
Price/Earning (TTM) 25.14
Price/Sales (TTM) 5.70
Price/Book (MRQ) 5.81
PAT Margin (%) 22.20
ROCE (%) 30.54
Incorporation Year : 1949

Management Info :

Premchand Godha - Chairman Premchand Godha - Managing Director

Registered Office :

Address : 48 , Kandivli Industrial Estate,Kandivli (West), ,
Mumbai,
Maharashtra-400067

Phone : 022- 66474444/62106050

Website : www.ipca.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
20Oct10-20-2021$IPCA Laboratories informs about board meeting IPCA Laboratories informs ab
IPCA Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 13/11/2021 to consider and approve the Standalone and Consolidated Unaudited financial results for the period ended September 30, 2021, Interim dividend, and sub-division of every 1 equity share of the nominal/face value of Rs 2 each into 2 equity shares of the nominal/face value of Re 1 each.

The above information is a part of company’s filings submitted to BSE.

IPCA Laboratories has informed that the meeting of the Board of..
01Oct10-01-2021$Ipca Laboratories’ arm picks up additional 20% share capital of Bayshore Ipca Laboratories’ arm pic

Ipca Laboratories’ wholly owned subsidiary -- Ipca Pharmaceuticals, Inc., USA has acquired further 20% share capital of Bayshore Pharmaceuticals LLC (Bayshore), a New Jersey limited liability company for $1.2 million. With this acquisition, Bayshore is now wholly owned by Ipca Pharmaceuitcals, Inc.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in many countries and its export accounts for around half of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates.

Ipca Laboratories’ wholly owned subsidiary -- Ipca Pharmaceut..
01Oct10-01-2021$ Announcement under Regulation 30 (LODR)-Acquisition Announcement under Regulati
Acquisition of further 20% share capital of Bayshore Pharmaceuticals LLC, New Jersey, USA by lpca Pharmaceuticals Inc.
Acquisition of further 20% share capital of Bayshore Pharmaceut..
13Sep09-13-2021$lpca Laboratories informs about investor meeting lpca Laboratories informs ab

Pursuant to Regulation 30 of the SESI (Listing Obligations and Disclosure Requirements) Regulations, 2015, lpca Laboratories has informed that the Company is participating in the virtual Annual Investor Conference organised by Motilal Oswal on Monday, 13th September, 2021 between 11.00 am to 12.00 noon. In this virtual investor meeting, only publicly available information will be shared with the Analysts/institutional investors.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SESI (Listing Obligations and..
09Aug08-09-2021$Ipca Laboratories informs about transcript of the conference call Ipca Laboratories informs ab

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it enclosed the transcript of the Conference Call held on Friday, 6th August, 2021 to discuss the Company's 01 FY22 earnings and business update.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the Securities and Exchange Board..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit2847.211407.7
Gross Profit 3563.7 13799.6
Operating Profit 4075.915758.2
Net Sales 1478651391.6
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20746.95 (0.93%)
M.Cap ( in Cr)
44085.82
Ajanta Pharma (BSE)
 2215.40 (2.45%)
M.Cap ( in Cr)
19171.13
Sanofi India (BSE)
 8117.95 (0.35%)
M.Cap ( in Cr)
18696.14
Mercury Laboratories (BSE)
 718.00 (3.16%)
M.Cap ( in Cr)
86.16
Suven Pharma (BSE)
 533.95 (1.75%)
M.Cap ( in Cr)
13592.50
Shareholding Pattern More
PROMOTERS 46.29 %
FI/BANKS/INSURANCE 3.36 %
MUTUAL FUNDS/UTI 21.49 %
NON-INSTITUTION 10.57 %
GOVERNMENT 0.22 %
FII 0 %
MF HOLDINGS More
F & O Quotes